Arsenic Trioxide and the Growth of Human T-cell Leukemia Virus Type I Infected T-cell Lines

References

• Shimoyama M., members of the Lymphoma Study Group. (1991) Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukemia/lymphoma. Br. J. Haematol. 1984–1987; 79: 428–437
   Web of Science ®Google Scholar
• Hanada S., Utsunomiya A., Suzuki S., Uozumi K., Makino T., Arima T. Treatment for adult T‐cell leukemia. Cancer Chemothel. Pharmacol. 1997; 40: 47–50, Suppl
   PubMed Web of Science ®Google Scholar
• Kuwazuru Y., Hanada S., Furukawa T., Yoshimura A., Sumizawa T., Utsunomiya A., Ishibashi K., Saito T., Uozumi K., Maruyama M., Ishizawa M., Arima T., Akiyama S. Expression of P‐glycoprotein in adult T‐cell leukemia cells. Blood 1990; 76: 2065–2071
   PubMed Web of Science ®Google Scholar
• Lau A., Nightingale S., Taylor G. P., Gant T. W., Cann A. J. Enhanced MDRl gene expression in human T‐cell leukemia virus‐I‐infected patients offers new prospects for therapy. Blood 1998; 91: 2467–2474
   PubMed Web of Science ®Google Scholar
• Ikeda K., Oka M., Yamada Y., Soda H., Fukuda M., Kinoshita A., Tsukamoto K., Noguchi Y., Isomoto H., Takeshima F., Murase K., Kamihira S., Tomonaga M., Kohno S. Adult T‐cell leukemia cells over‐express the multidrug‐resistance‐protein (MRP) and lung‐resistance‐protein (LRP) genes. Int. J. Cancer 1999; 82: 599–604
   PubMed Web of Science ®Google Scholar
• Takatsuki K., Yamaguchi K., Hattori T. Adult T‐cell leukemia/Iymphoma. Retrovirus biology and human disease, R. C. Gallo, F. Wong‐Staal, 1990; 147–159
   Google Scholar
• Shen Z. X., Chen G. Q., Ni J. H., Li X. S., Xiong S. M., Qiu Q. Y., Zhu J., Tang W., Sun G. L., Yang K. Q., Chen Y., Zhou L., Fang Z. W., Wang Y. T., Ma J., Zhang P., Zhang T. D., Chen S. J., Chen Z., Wang Z. Y. Use of arsenic trioxide (As2O3) in the treatment of acute promyelo‐cytic leukemia (APL): II. Clinical efficacy and pharmacoki‐netics in relapsed patients. Blood 1997; 89: 3354–60
   PubMed Web of Science ®Google Scholar
• Chen G. Q., Zhu J., Shi X. G., Ni J. H., Zhong H. J., Si G. Y., Jin X. L., Tang W., Li X. S., Xong S. M., Shen Z. X., Sun G. L., Ma J., Zhang P., Zhang T. D., Gazin C., Naoe T., Chen S. J., Wang Z. Y., Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As203 induces NB4 cell apoptosis with downregulation of bcl‐2 expression and modulation of PML‐RARα/PML proteins. Blood 1996; 88: 1052–1061
   PubMed Web of Science ®Google Scholar
• Soignet S. L., Maslak P., Wang Z. G., Jhanwar S., Calleja E., Dardashti L. J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D. A., Pandolfi P. P., Warrell R. P., Jr. Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide. N. Engl. J. Med. 1998; 339: 1341–1348
   PubMed Web of Science ®Google Scholar
• Zhang W., Ohnishi K., Shigeno K., Fujisawa S., Naito K., Nakamura S., Takeshita K., Takeshita A., Ohno R. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998; 12: 1383–1391
   PubMed Web of Science ®Google Scholar
• Dai J., Weinberg R. S., Waxman S., Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268–277
   PubMed Web of Science ®Google Scholar
• Zhu X. H., Shen Y. L., Jing Y. K., Cai X., Jia P. M., Huang Y., Tang W., Shi G. Y., Sun Y. P., Dai J., Wang Z. Y., Chen S. J., Zhang T. D., Waxman S., Chen Z., Chen G. Q. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J. Natl. Cancel. Inst. 1999; 91: 772–778
   PubMed Web of Science ®Google Scholar
• Konig A., Wrazel L., Warrell R. P., Jr, Rivi R., Pandolfi P. P., Jakubowski A., Gabrilove J. L. Comparative activity of melarsoprol and arsenic trioxide in chronic B‐cell leukemia lines. Blood 1997; 90: 562–70
   PubMed Web of Science ®Google Scholar
• Rousselot P., Labaume S., Marolleau J. P., Larghero J., Noguera M. H., Brouet J. C., Fermand J. P. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res. 1999; 59: 1041–1048
   PubMed Web of Science ®Google Scholar
• Miyoshi I., Kubonishi I., Sumida M., Hiraki S., Tsubota T., Kimura I., Miyamoto K., Sato J. A novel T‐cell line derived from adult T‐cell leukemia. Gann 1980; 71: 155–156
   PubMedGoogle Scholar
• Miyoshi I., Kubonishi I., Yoshimoto S., Shiraishi Y. A T‐cell line derived from normal human cord leukocytes by co‐culturing with human leukemic T‐cells. Gann 1981; 72: 978–981
   PubMedGoogle Scholar
• Hanada S., Tsubai F., Namba Y. The characteristics of T‐cell lines derived from peripheral blood of patients with adult T‐cell leukemia‐lymphoma. Recent Advances in RES Research 1985; 25: 124
   Google Scholar
• Ishitsuka K., Hanada S., Suzuki S., Utsunomiya A., Chyu‐man Y., Takeuchi S., Takeshita T., Shimotakahara S., Uozumi K., Makino T., Arima T. Arsenic trioxide inhibits growth of human T‐cell leukumia virus type I infected T‐cell lines more effectively than retinoic acids. Br. J. Haematol. 1998; 103: 721–728
   PubMed Web of Science ®Google Scholar
• Bazarbachi A., EL‐Sabban M. E., Nasr R., Quignon F., Awaraji C., Kersual J., Dianoux L., Zernati Y., Haider J. H., Hermine O., de The H. Arsenic trioxide and interferon‐α synergize to induce cell cycle arrest and apoptosis in human T‐cell lymphotrophic virus type I‐trans‐formed cells. Blood 1999; 93: 278–283
   PubMed Web of Science ®Google Scholar
• Ishitsuka K., Kitazono M., Hanada S., Suzuki S., Utsunomiya A., Takeshita T., Uozumi K., Akiyama S., Arima T. Arsenic trioxide induces apoptosis and cell cycle arrest at G1 phase to HTLV‐I infected T‐cell lines with modulation of bak and Kipl/p27 expression. Blood 1998; 92(Suppl 1)245a
   Google Scholar
• Zamai L., Falcieri E., Zauli G., Cataldi A., Vitale M. Optimal detection of apoptosis by flow cytometry depends on cell morphology. Cytometry; 1993; 14: 891–897
   PubMedGoogle Scholar
• Gavrieli Y., Sherman Y., Ben‐Sasson S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J, Cell, Biol. 1992; 119: 493–501
   PubMed Web of Science ®Google Scholar
• Zhang C., Ao Z., Seth A., Schlossman S. F. A mitochondria1 membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. J Immunol. 1996; 157: 3980–3987
   PubMed Web of Science ®Google Scholar
• Vermes I., Haanen C., Steffens‐Nakken H., Reuteling‐sperger C. J. A novel assay for apoptosis. Flow cyto‐metric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods. 1995; 184: 39–51
   PubMed Web of Science ®Google Scholar
• Hockenbery D. M., Oltvai Z. N., Yin X. M., Milliman C. L., Korsmeyer S. J. Bcl‐2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241–251
   PubMed Web of Science ®Google Scholar
• Reed J. C. Bcl‐2 and the regulation of programmed cell death. J. Cell. Biol. 1994; 124: 1–6
   PubMed Web of Science ®Google Scholar
• Boise L. H., Gonzalez G. M., Postema C. E., Ding L., Lind‐sten T., Turka L. A., Mao X., Nunez G., Thompson C. B. bcl‐X, a bcl‐2‐related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597–608
   PubMed Web of Science ®Google Scholar
• Oltvai Z. N., Milliman C. L., Korsmeyer S. J. Bcl‐2 heterodimerizes in vivo with a conserved homolog. Bax, that accelerates programmed cell death. Cell 1993; 74: 609–619
   PubMed Web of Science ®Google Scholar
• Farrow S. N., White J. H., Martinou I., Raven T., Pun K. T., Grinham C. J., Martinou J. C., Brown R. Cloning of a bcl‐2 homologue by interaction with adenovirus E1B 19K. Nature 1995; 374: 731–733
   PubMed Web of Science ®Google Scholar
• Chittenden T., Harrington E. A., O'Connor R., Flemington C., Lutz R. J., Evan G. I., Guild B. C. Induction of apoptosis by the Bcl‐2 homologue Bak. Nature 1995; 374: 733–736
   PubMed Web of Science ®Google Scholar
• Cheng E. H., Kirsch D. G., Clem R. J., Ravi R., Kastan M. B., Bedi A., Ueno K., Hardwick J. M. Conversion of Bcl‐2 to a Bax‐like death effector by caspases. Science 1997; 278: 1966–1968
   PubMed Web of Science ®Google Scholar
• Fujita N., Tsuruo T. Involvement of Bcl‐2 cleavage in the acceleration of VP‐16‐induced U937 cell apoptosis. Biomed. Biophys. Res. Com. 1998; 246: 484–488
   PubMed Web of Science ®Google Scholar
• Sherr C. J. Mammalian GI cyclins. Cell 1993; 73: 1059–1065
   PubMed Web of Science ®Google Scholar
• Weinberg R. A. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323–330
   PubMed Web of Science ®Google Scholar
• Morgan D. O. Principles of CDK regulation. Nature 1995; 274: 131–134
   Web of Science ®Google Scholar
• Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk‐interacting protein Cipl is a potent inhibitor of G1 cyclin‐dependent kinases. Cell 1993; 75: 805–816
   PubMed Web of Science ®Google Scholar
• Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin‐Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67–74
   PubMed Web of Science ®Google Scholar
• Levine A. J. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323–31
   PubMed Web of Science ®Google Scholar
• Sakashita A., Hattori T., Miller C. W., Suzushima H., Asou N., Takatsuki K., Koeffler H. P. Mutations of the p53 gene in adult T‐cell leukemia. Blood 1992; 79: 477–480
   PubMed Web of Science ®Google Scholar
• Yamato K., Oka T., Hiroi M., Iwahara Y., Sugito S., Tsuchida N., Miyoshi I. Aberrant expression of the p53 tumor suppressor gene in adult T‐cell leukemia and HTLV‐I‐infected cells. Jpn. J. Cancer. Res. 1993; 84: 4–8
   PubMedGoogle Scholar
• Rowan S., Ludwig R. L., Haupt Y., Bates S., Lu X., Oren M., Vousden K. H. Specific loss of apoptotic but not cell‐cycle arrest function in a human tumor derived p53 mutant. EMBO J. 1996; 15: 827–38
   PubMed Web of Science ®Google Scholar
• Hatta Y., Hirama T., Miller C. W., Yamada Y., Tomonaga M., Koeffler H. P. Homozygous deletions of the p15 (MTS2) and p16 (CDKN2NTS1) genes in adult T‐cell leukemia. Blood 1995; 85: 2699–2704
   PubMed Web of Science ®Google Scholar
• Morosetti R., Kawamata N., Gombart A. F., Miller C. W., Hatta Y., Hirama T., Said J. W., Tomonaga M., Koeffler H. P. Alterations of the p27KIP1 gene in non‐Hodg‐kin's lymphomas and adult T‐cell leukemidymphoma. Blood 1995; 86: 1924–1930
   PubMed Web of Science ®Google Scholar
• Shiohara M., el‐Deiry W. S., Wada M., Nakamaki T., Takeuchi S., Yang R., Chen D. L., Vogelstein B., Koeffler H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781–3784
   PubMed Web of Science ®Google Scholar
• Hatta Y., Yamada Y., Tomonaga M., Koeffler H. P. Extensive analysis of the retinoblastoma gene in adult T cell leukemiadymphoma (ATL). Leukemia 1997; 11: 984–989
   PubMed Web of Science ®Google Scholar
• U‐Taniguchi Y., Furuke K., Masutani H., Nakamura H., Yodoi J. Cell cycle inhibition of HTLV‐I transformed T cell lines by retinoic acid: the possible therapeutic use of thioredoxin reductase inhibitors. Oncol. Res. 1995; 7: 183–189
   PubMed Web of Science ®Google Scholar
• Huang S. Y., Chang C. S., Tang J. L., Tien H. F., Kuo T. L., Huang S. F., Yao Y. T., Chou W. C., Chung C. Y., Wang C. H., Shen M. C., Chen Y. C. Acute and chronic arsenic poisoning associated with treatment of acute promye‐locytic leukaemia. BK J. Haematol. 1998; 103: 1092–1095
   PubMed Web of Science ®Google Scholar